NCT04533841

Brief Summary

To compare propranolol and misoprostol versus misoprostol alone for induction of labour in primigravidas

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Feb 2020

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2020

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 26, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 1, 2020

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 13, 2020

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2020

Completed
Last Updated

August 31, 2022

Status Verified

August 1, 2022

Enrollment Period

8 months

First QC Date

August 26, 2020

Last Update Submit

August 30, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Induction delivery interval

    The time from starting induction to the delivery

    procedure delivery

Secondary Outcomes (1)

  • Mode of delivery

    delivery

Study Arms (2)

Misoprostol + propranolol

ACTIVE COMPARATOR

Patient who receive misoprostol then after 30minutes receive propranolol

Drug: MisoprostolDrug: Propranolol

Misoprostol + placebo

PLACEBO COMPARATOR

Pt who will receive misoprostol then after 30minutes receive placebo

Drug: MisoprostolDrug: Placebo

Interventions

Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol

Misoprostol + placeboMisoprostol + propranolol

placebo

Misoprostol + placebo

Propranolol

Misoprostol + propranolol

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale full term pregnancy primigravida
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Primigravidas.
  • Full term patients with ultrasound confirmed dates.
  • Singleton.
  • Cephalic presentation.
  • Fetal heart rate between 120 to 160 beats per minute.

You may not qualify if:

  • Any history of previous surgery on the uterus.
  • Patients in active labour, with ruptured membranes.
  • Fetal distress.
  • Macrosomia or polyhydramnios
  • Hypersensitivity to prostaglandins.
  • Asthmatic patient .
  • liver or kidney impairment .
  • known cardiac patient with abnormal ECG.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed mohamed fathy ismail

Zagazig, El Sharquia, 055, Egypt

Location

Related Publications (1)

  • Abdel Hamid AS, El Zeneiny H, Fathy A, Nawara M. A pilot study to compare propranolol and misoprostol versus misoprostol and placebo for induction of labor in primigravidae; a randomized, single-blinded, placebo-controlled trial. BMC Pregnancy Childbirth. 2023 Apr 4;23(1):226. doi: 10.1186/s12884-023-05537-1.

MeSH Terms

Interventions

MisoprostolPropranolol

Intervention Hierarchy (Ancestors)

Prostaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological FactorsPhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic Compounds

Study Officials

  • Ahmed S Abd El hamid, A.professor

    Ain Shams University

    STUDY DIRECTOR
  • Hazem A Hassan elzeneiny, Professor

    Ain Shams University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double blinded research
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Clinical trial
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

August 26, 2020

First Posted

September 1, 2020

Study Start

February 1, 2020

Primary Completion

September 13, 2020

Study Completion

September 15, 2020

Last Updated

August 31, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will share

Study results will be available

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
September 2020
Access Criteria
Researchers

Locations